Form 4: Ultragenyx EVP Karah Parschauer Reports Stock Transactions
SEC Form 4 Filing
EVP and Chief Legal Officer of Ultragenyx Pharmaceutical Inc., Karah Parschauer, reports acquisition and disposal of company stock related to performance stock units and tax obligations.
Summary
- On March 1, 2025, Karah Parschauer, EVP and Chief Legal Officer of Ultragenyx Pharmaceutical Inc., acquired 18,443 shares of common stock upon conversion of performance stock units.
- The acquisition price was $0.
- On March 3, 2025, Parschauer sold 12,846 shares of common stock at a weighted average price of $42.1, with prices ranging from $41.77 to $42.90.
- The sale was to cover required tax withholdings due to the vesting of RSUs.
- Following these transactions, Parschauer beneficially owns 75,287 shares of Ultragenyx common stock, including shares underlying previously granted RSUs.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions, with no inherent positive or negative implications for the company's performance.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.
Key Dates
| Date | Description |
|---|---|
| 03/01/2025 | Conversion of performance stock units into 18,443 shares of common stock. |
| 03/03/2025 | Sale of 12,846 shares of common stock at an average price of $42.1. |
| 03/04/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.